Transmedics Group Inc

TMDX has broken below key moving averages and failed to sustain its recent advance, shifting the medium-term bias to bearish while the long-term trend remains negative under a declining 200DMA. Short-term momentum confirms the downside as price rejects EMAs and RSI turns down. Execution favors selling on rallies into the former support-turned-resistance zone.

• ↑Q2 revenue of $190 M grew 21% YoY, led by 29% service revenue growth
• ↑Full-year 2026 revenue guidance increased 22–25% YoY to $737–757 M
• ↓EPS down 52% YoY amid rising operating expenses